ALX ONCOLOGY HOLDINGS INC Investment Income, Interest
ALX ONCOLOGY HOLDINGS INC (ALXO) reported Investment Income, Interest of $1.51 million for the 3-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Income Statement › Other Income
us-gaap:InvestmentIncomeInterest · last filed 2026-08-06
- ALX ONCOLOGY HOLDINGS INC investment income, interest for the quarter ending 2026-06-30 was $1.51M, a 36.35% increase year-over-year.
- ALX ONCOLOGY HOLDINGS INC investment income, interest for the quarter ending 2026-03-31 was $1.18M, a 20.30% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC investment income, interest for the quarter ending 2025-12-31 was $573.00K, a 69.49% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC investment income, interest for the quarter ending 2025-09-30 was $802.00K, a 65.18% decline year-over-year.
- ALX ONCOLOGY HOLDINGS INC investment income, interest for fiscal 2025 was $3.96M, a 57.68% decline from fiscal 2024.
- ALX ONCOLOGY HOLDINGS INC investment income, interest for fiscal 2024 was $9.37M, a 12.05% decline from fiscal 2023.
- ALX ONCOLOGY HOLDINGS INC investment income, interest for fiscal 2023 was $10.65M, a 148.92% increase from fiscal 2022.
- ALX ONCOLOGY HOLDINGS INC investment income, interest for fiscal 2022 was $4.28M, a 4601.10% increase from fiscal 2021.
| Period end | Investment Income, Interest 3 month | Investment Income, Interest 6 month | Investment Income, Interest 9 month | Investment Income, Interest 12 month |
|---|---|---|---|---|
| 2026-06-30 | $1.51M 10-Q · filed 2026-08-06 | $2.69M 10-Q · filed 2026-08-06 | $3.26M derived: sum of 3 quarters · filed 2026-08-06 | $4.07M derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | $1.18M 10-Q · filed 2026-05-08 | $1.75M derived: sum of 2 quarters · filed 2026-05-08 | $2.56M derived: sum of 3 quarters · filed 2026-05-08 | $3.66M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-12-31 | $573.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $1.38M derived: sum of 2 quarters · filed 2026-03-09 | $2.48M derived: sum of 3 quarters · filed 2026-08-06 | $3.96M 10-K · filed 2026-03-09 |
| 2025-09-30 | $802.00K 10-Q · filed 2025-11-07 | $1.91M derived: sum of 2 quarters · filed 2026-08-06 | $3.39M 10-Q · filed 2025-11-07 | $5.27M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-06-30 | $1.11M 10-Q · filed 2026-08-06 | $2.59M 10-Q · filed 2026-08-06 | $4.47M derived: sum of 3 quarters · filed 2026-08-06 | $6.77M derived: sum of 4 quarters · filed 2026-08-06 |
| 2025-03-31 | $1.48M 10-Q · filed 2026-05-08 | $3.36M derived: sum of 2 quarters · filed 2026-05-08 | $5.66M derived: sum of 3 quarters · filed 2026-05-08 | $8.23M derived: sum of 4 quarters · filed 2026-05-08 |
| 2024-12-31 | $1.88M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $4.18M derived: sum of 2 quarters · filed 2026-03-09 | $6.74M derived: sum of 3 quarters · filed 2026-03-09 | $9.37M 10-K · filed 2026-03-09 |
| 2024-09-30 | $2.30M 10-Q · filed 2025-11-07 | $4.87M derived: sum of 2 quarters · filed 2025-11-07 | $7.49M 10-Q · filed 2025-11-07 | $10.48M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-06-30 | $2.56M 10-Q · filed 2025-08-12 | $5.18M 10-Q · filed 2025-08-12 | $8.18M derived: sum of 3 quarters · filed 2026-03-09 | $10.86M derived: sum of 4 quarters · filed 2026-03-09 |
| 2024-03-31 | $2.62M 10-Q · filed 2025-05-08 | $5.62M derived: sum of 2 quarters · filed 2026-03-09 | $8.29M derived: sum of 3 quarters · filed 2026-03-09 | $10.96M derived: sum of 4 quarters · filed 2026-03-09 |
| 2023-12-31 | $3.00M derived: 10-K 12 month − 10-Q 9 month · filed 2026-03-09 | $5.67M derived: sum of 2 quarters · filed 2026-03-09 | $8.34M derived: sum of 3 quarters · filed 2026-03-09 | $10.65M 10-K · filed 2026-03-09 |
| 2023-09-30 | $2.68M 10-Q · filed 2024-11-07 | $5.34M derived: sum of 2 quarters · filed 2024-11-07 | $7.65M 10-Q · filed 2024-11-07 | $9.46M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-06-30 | $2.67M 10-Q · filed 2024-08-12 | $4.98M 10-Q · filed 2024-08-12 | $6.78M derived: sum of 3 quarters · filed 2025-03-06 | $8.15M derived: sum of 4 quarters · filed 2025-03-06 |
| 2023-03-31 | $2.31M 10-Q · filed 2024-05-09 | $4.12M derived: sum of 2 quarters · filed 2025-03-06 | $5.49M derived: sum of 3 quarters · filed 2025-03-06 | $6.36M derived: sum of 4 quarters · filed 2025-03-06 |
| 2022-12-31 | $1.81M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-06 | $3.18M derived: sum of 2 quarters · filed 2025-03-06 | $4.05M derived: sum of 3 quarters · filed 2025-03-06 | $4.28M 10-K · filed 2025-03-06 |
| 2022-09-30 | $1.37M 10-Q · filed 2023-11-13 | $2.25M derived: sum of 2 quarters · filed 2023-11-13 | $2.47M 10-Q · filed 2023-11-13 | |
| 2022-06-30 | $876.00K 10-Q · filed 2023-08-10 | $1.10M 10-Q · filed 2023-08-10 | ||
| 2022-03-31 | $225.00K 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | $91.00K 10-K · filed 2024-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Fortress Biotech, Inc. (FBIO) | United States | $0.188B | 0.91 |
| PepGen Inc. (PEPG) | United States | $0.186B | -1.73 |
| AN2 Therapeutics, Inc. (ANTX) | United States | $0.185B | -4.84 |
| Organogenesis Holdings Inc. (ORGO) | United States | $0.182B | -3.70 |
| Zentalis Pharmaceuticals, Inc. (ZNTL) | United States | $0.196B | -2.48 |
| ORAMED PHARMACEUTICALS INC. (ORMP) | $0.199B | 1.13 | |
| Nkarta, Inc. (NKTX) | United States | $0.205B | -1.73 |
| Tonix Pharmaceuticals Holding Corp. (TNXP) | United States | $0.166B | -1.34 |
| Minerva Neurosciences, Inc. (NERV) | United States | $0.165B | -0.66 |
| ADC Therapeutics SA (ADCT) | $0.163B | -1.39 |